Weinheim, Germany

Axel Tuchlenski

This inventor holds 12 USPTO granted patents and 1 published patent application and 4 EPO patents. Top assignees: Oxeno Olefinchemie Gmbh, Evonik Oxeno Gmbh. Active years: 2003-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Axel Tuchlenski. Retrieved from https://idiyas.com/inventor/axel-tuchlenski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 

% Patents Active = 41.7


Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 77(Granted Patents)


Location History:

  • Recklinghausen, DE (2003)
  • Mülheim, DE (2010)
  • Muelheim, DE (2006 - 2011)
  • Weinheim, DE (2006 - 2013)

Company Filing History:


Years Active: 2003-2013

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: Inventor Axel Tuchlenski

Introduction: Axel Tuchlenski is a renowned inventor based in Weinheim, Germany, known for his groundbreaking contributions to various technological fields.

Latest Patents: Axel Tuchlenski holds several patents in the areas of renewable energy, sustainable materials, and advanced manufacturing processes.

Career Highlights: With a career spanning over two decades, Axel Tuchlenski has worked with leading research institutions and companies to develop innovative solutions that have had a significant impact on the industry.

Collaborations: Throughout his career, Axel Tuchlenski has collaborated with top engineers, scientists, and designers to bring his inventions to life, resulting in successful commercialization and widespread adoption.

Conclusion: Axel Tuchlenski's dedication to pushing the boundaries of innovation and his passion for creating sustainable technologies make him a key figure in the world of inventors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…